{"url_path":"/sec/mplt/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1770069/0001193125-26-224129-index.html","accession_number":"0001193125-26-224129","cik":"0001770069","ticker":"MPLT","issuer_name":"MapLight Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1770069/0001193125-26-224129-index.html","primary_entity_key":"0001770069","primary_entity_name":"MapLight Therapeutics, Inc."},"word_count":398,"has_tables":true,"body_markdown":"Item 6. Exhibits\n\nThe exhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which is incorporated herein by reference.\n\nExhibit Index\n\n \n\nExhibit\n\nNumber\n\nDescription\n\n3.1\n\n \n\n[Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-42914) filed with the SEC on October 29, 2025)](https://www.sec.gov/Archives/edgar/data/1770069/000119312525255041/d89036dex31.htm)\n\n3.2\n\n \n\n[Amended and Restated Bylaws of the Registrant (incorporated herein by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K (File No. 001-42914) filed with the SEC on October 29, 2025)](https://www.sec.gov/Archives/edgar/data/1770069/000119312525255041/d89036dex32.htm)\n\n10.1*+\n\n \n\n[Non-Employee Director Compensation Policy](mplt-ex10_1.htm)\n\n31.1*\n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](mplt-ex31_1.htm)\n\n31.2*\n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](mplt-ex31_2.htm)\n\n32.1†\n\n[Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](mplt-ex32_1.htm)\n\n101.INS\n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n* Filed herewith.\n\n† This certification is being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.\n\n+ Indicates management contract or compensatory plan.\n\n72\n\n[Table of Contents](#toc_page)\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nMapLight Therapeutics, Inc.\n\n \n\nDate: May 14, 2026\n\nBy:\n\n/s/ Christopher A. Kroeger\n\n \n\nChristopher A. Kroeger, M.D.\n\n \n\nChief Executive Officer\n\n \n\n(Principal Executive Officer)\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDate: May 14, 2026\n\nBy:\n\n/s/ Vishwas Setia\n\n \n\n \n\n \n\nVishwas Setia\n\n \n\n \n\n \n\nChief Financial Officer\n\n \n\n \n\n \n\n(Principal Financial Officer)\n\n \n\n73"}